newsfilter
← Latest News
PR Newswire·

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Interim data from SUNRISE trial in four pediatric patients showed detectable levels of ALB-2A biomarker demonstrating site-specific gene insertion and protein expression - Two of four patients demonstrated increasing ALB-2A levels over time, indicati